Wechselwirkungen · Bridion
Bridion 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 6
HOS-119609 · Präparat HOS-094981
Interactions potentially affecting the efficacy of sugammadex (displacement interactions): Due to the administration of certain medicinal products after sugammadex, theoretically rocuronium or vecuronium could be displaced from sugammadex. As a result recurrence of neuromuscular blockade might be observed. In this situation the patient must be ventilated. Administration of the medicinal product which caused displacement should be stopped in case of an infusion. In situations when potential displacement interactions can be anticipated, patients should be carefully monitored for signs of recurrence of neuromuscular blockade (approximately up to 15 minutes) after parenteral administration of another medicinal product occurring within a period of 7.5 hours after sugammadex administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vecuronium (HOS-119611) rocuronium (HOS-119610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-06T17:24:00Z · SHA-256 c678da8df4e0f062258fc41e9097613813dcaaecc8e8156e47a2d8252e6efd4e · Passage 51fe9195e7e962d3a0bf4fee1b671d0aad66b22bd01fc6d36f0e973e97adcf44 · Zeichen 786–1581 im Abschnitt